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Abstract
Background: Ketamine rapidly elicits antidepressive effects in humans and mice in which serotonergic activity is involved. 
Although α4β2 nicotinic acetylcholine receptor (α4β2 nAChR) in the dorsal raphe nucleus plays a key role in the ketamine-
induced prefrontal serotonin release, the source of cholinergic afferents, and its role is unclear.
Methods: Prefrontal serotonin levels after ketamine injection were measured by microdialysis in rats. Electrolytic lesion of 
pedunculopontine tegmental nucleus and laterodorsal tegmental nucleus was made with constant direct current.
Results: Bilateral lesion of the pedunculopontine tegmental nucleus, but not laterodorsal tegmental nucleus, attenuated 
prefrontal serotonin release induced by systemic ketamine. Intra-pedunculopontine tegmental nucleus, but not intra-
laterodorsal tegmental nucleus ketamine perfusion, increased prefrontal serotonin release. This increase was attenuated 
by intra-dorsal raphe nucleus injection of dihydro-β-erythroidine, an α4β2 nAChR antagonist, or NBQX, an AMPA receptor 
antagonist.
Conclusions: These results suggest the ketamine-induced serotonin release in medial prefrontal cortex is mediated by 
cholinergic neurons projecting from pedunculopontine tegmental nucleus to dorsal raphe nucleus via α4β2 nAChRs.
Keywords: ketamine, serotonin, microdialysis, nicotinic acetylcholine receptors, raphe
Introduction
Major depressive disorder (MDD) is one of the most common 
mental disorders in the world. Although MDD patients are 
often treated with antidepressants such as selective serotonin 
reuptake inhibitors (SSRIs), chronic administration for several 
weeks is required for therapeutic efficacy. Furthermore, around 
one-third of MDD patients are resistant to the conventional 
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drug treatment (Rush et  al., 2006; Belmaker and Agam 2008). 
Therefore, rapid-acting antidepressants with higher efficacy 
are urgently needed. Clinical studies have revealed that an 
N-methyl-D-aspartate receptor (NMDAR) antagonist, ketamine, 
at a subanesthetic dose rapidly elicits antidepressive action 
in the treatment-resistant MDD patients (Berman et  al., 2000; 
Zarate et al., 2006). In rodents, ketamine produces antidepres-
sant-like effects in a variety of behavioral paradigms such as 
forced swim test and novelty-suppressed feeding test, which 
are attenuated by depletion of serotonin (Gigliucci et al., 2013; 
Fukumoto et al., 2014). On the other hand, acute administration 
of ketamine enhanced extracellular serotonin levels in the med-
ial prefrontal cortex (mPFC), one of the brain regions associated 
with the pathology of MDD (Amargós-Bosch et al., 2006). These 
reports indicate that serotonergic neural transmission mediates 
the effect of ketamine, although the precise mechanism how 
ketamine activates serotonergic neurons is unclear.
It has been reported that endogenous acetylcholine (ACh) and 
nicotine activate serotonin neurons by increasing glutamate re-
lease through activation of presynaptic α4β2 nicotinic acetylcho-
line receptors (α4β2 nAChRs) in the dorsal raphe nucleus (DRN) 
(Garduño et  al., 2012). Consistent with these studies, we have 
reported that systemic ketamine injection increases serotonin 
levels in the mPFC through indirectly activating α4β2 nAChRs 
in the DRN (Nishitani et al., 2014). These reports have raised the 
possibility that the cholinergic neurons projecting to the DRN 
are involved in ketamine-induced serotonin release. The DRN 
receives cholinergic innervation from the pedunculopontine 
tegmental nucleus (PPTg) and laterodorsal tegmental nucleus 
(LDTg), where large clusters of cholinergic neurons are anatomic-
ally defined at the junction of the midbrain and pons (Woolf and 
Butcher, 1989). However, the role of these cholinergic nuclei in the 
regulation of serotonergic activity remains to be unveiled.
In this study, we investigated the role of DRN-projecting PPTg 
and LDTg neurons in the ketamine-induced serotonin release in 
mPFC by in vivo microdialysis in rats.
Methods
All animal care and experimental procedures were in accord-
ance with the ethical guidelines of the Kyoto University Animal 
Research Committee and approved by the Kyoto University 
Animal Research Committee. Male Wistar/ST rats (8–12 weeks 
of age, 220–350  g; Nihon SLC) were used. The animals were 
housed in groups of 3 per cage with free access to food and water 
and kept under controlled conditions (12-h-light/-dark cycle; 
24 ± 1°C). All surgeries were performed on rats anesthetized with 
sodium pentobarbital (60 mg/kg i.p.). Electrolytic lesions of the 
PPTg (AP −7.8 mm, ML ±1.9 mm, DV +7.6 mm from the bregma, 
according to the Brain Atlas; Paxinos and Watson, 2007) or LDTg 
(AP −8.7 mm, ML ±0.8 mm, DV +7.0 mm) were made bilaterally 
using stainless-steel pipe (30 gauge) insulated except the tip. 
Lesions were made with anodal constant direct current at each 
location (25 V for 25 s). Sham operations were performed in an 
identical manner, but no current was passed through. After a 7-d 
recovery period, the animals were implanted with the guide can-
nula for microdialysis procedures. Each rat was stereotaxically 
implanted with guide cannula (Eicom) in the mPFC (AP +3.2 mm, 
ML +0.6 mm or −0.6 mm, DV +4.0 mm) for in vivo microdialysis, 
in the DRN (AP −7.7 mm, ML +2.4 mm, DV +7.0 mm) for local drug 
microinjection, and in the PPTg (AP −7.9  mm, ML +1.9  mm or 
−1.9 mm, DV +7.0 mm) and LDTg (AP −8.7 mm, ML +0.8 mm, DV 
+6.0) for local drug perfusion. The guide cannulae were secured 
to the skull with dental cement. After 1 to 2 d of recovery period, 
microdialysis experiments were performed in unanesthetized 
and freely moving rats. Microdialysis probes (membrane length 
2 mm, o.d. 0.22 mm; Eicom) in the mPFC were inserted through the 
guide cannula and perfused at a constant flow of 1 μL/min with 
Ringer buffer (147 mM NaCl, 4 mM KCl, 2.3 mM CaCl2) contain-
ing 1 μM citalopram (LKT Laboratories Inc.). Microdialysis probes 
(membrane length 1 mm, o.d. 0.22 mm; Eicom) for drug perfusion 
of PPTg or LDTg were also inserted through the guide cannula 
and perfused at a constant flow of 1 μL/min with Ringer buffer. 
Dialysates in the mPFC were collected every 10 min and immedi-
ately analyzed by high-performance liquid chromatography with 
electrochemical detector (Eicom). Serotonin was separated on a 
reverse phase column (PPII-ODS column, 3.0 φ × 150 mm; Eicom) 
and quantified by reference to a linear calibration curve, as previ-
ously described (Nishitani et al., 2014). Ketamine (Ketalar; Daiichi 
Sankyo Propharma Co., Ltd.) was administered s.c. or locally 
perfused into the PPTg or LDTg through microdialysis probes. 
For local perfusion of PPTg or LDTg with ketamine, we used the 
concentration of 0.1 mM in Ringer buffer. Dihydro-β-erythroidine 
(DHβE; Santa Cruz Biotechnology) and 2,3-dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX; Sigma-
Aldrich), an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor (AMPAR) antagonist, were dissolved in sterile saline 
(Otsuka Pharmaceutical Co., Ltd.) and microinjected into the 
DRN through the injection cannula (28 gauge). In microdialysis 
experiments, all drugs were administered after 3 to 4 h of sta-
bilization period. Intra-DRN drug microinjection (1 μL) was per-
formed at 0.2 μL/min for 5 min by microinfusion pump 10 min 
before local perfusion with ketamine. After all tests, histological 
verification of lesion location was performed. Rats were per-
fused across the heart with PBS followed by 4% paraformalde-
hyde (Nacalai Tesque) in 0.1 M phosphate buffer. The dissected 
brains were cryoprotected in 15% sucrose-PBS for overnight and 
frozen at −80°C for storage. The brains were cryosectioned into 
30-μm-thick coronal sections with the cryostat (Leica CM3050S; 
Leica Biosystems) and stored at −80°C until immunohistochemi-
cal processing. For immunohistochemistry, the sections were 
immersed in PBS with 0.25% Triton-X 100 (Nacalai Tesque) for 
permeabilization and then incubated overnight at 4°C with 
goat polyclonal anti-choline acetyltransferase (ChAT) antibody 
(1:200; AB144P, Merck Millipore), followed by incubation with 
Alexa Fluor 594-labeled donkey anti-goat IgG (1:200; Thermo 
Fisher Scientific) for 2 h at room temperature. The sections were 
then washed in PBS and mounted on glass with VECTASHIELD 
(Vector Laboratories). Immunofluorescence was visualized using 
a laser scanning confocal microscopy (Fluoview FV10i, Olympus). 
Histological analyses were performed to verify the placement 
of each tip of microdialysis probe (Nissl stain) or injection can-
nula (Evans Blue injection). The animals, in which the tips were 
incorrectly located, were excluded from the final analysis. Data 
are presented as means ± SEM of the percentage of the basal 
values calculated as an average of 4 consecutive dialysate just 
before drug administration. No significant difference in the basal 
values was observed throughout the study. Statistical analysis 
was performed by GraphPad Prism 5 (GraphPad). Microdialysis 
results were analyzed by 2-way ANOVA for repeated measures, 
followed by Bonferroni posthoc test. The number of ChAT posi-
tive cells after electrolytic lesion was analyzed by Student’s t test. 
Differences of P < .05 were considered statistically significant.
Results
The DRN is mainly innervated by cholinergic neurons from the 
PPTg and LDTg (Woolf and Butcher 1989). Therefore, we examined 
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the effect of bilateral lesion of PPTg or LDTg on ketamine-induced 
serotonin release in the mPFC. Histological analyses revealed that 
PPTg-lesion and LDTg-lesion rats had significantly fewer ChAT 
positive cells than each sham-operated rat (PPTg sham 105.2 ± 4.3 
cells, lesion 25.5 ± 7.5 cells; t7 = 9.711, P < .001, LDTg sham 198.0 ± 11.0 
cells, lesion 32.6 ± 6.7 cells; t8 = 12.88, P < .001; Figure  1A-D). 
Microdialysis was performed in these rats. Consistent with pre-
vious studies (Amargós-Bosch et al., 2006; Nishitani et al., 2014), 
acute administration of ketamine (30 mg/kg, s.c.) rapidly increased 
serotonin release in the mPFC in sham-operated rats. The PPTg 
lesion significantly attenuated the ketamine-induced serotonin 
release in the mPFC (F1,84 = 12.74, P < .01; Figure  1E), whereas the 
LDTg lesion did not (F1,96 = 2.703, P = .1388; Figure 1F).
Then we investigated whether ketamine directly affects the 
PPTg. Unilateral local perfusion of PPTg with ketamine (0.1 mM) 
significantly increased the serotonin release in the mPFC 
(F1,72 = 13.94, P < .01; Figure 2A), indicating that ketamine increases 
prefrontal serotonin release through action on the PPTg. By con-
trast, local perfusion of LDTg with ketamine (0.1 mM) did not 
affect serotonin release (F1,84 = 0.2563, P = .6282; Figure 2B).
Since intra-DRN injection of DHβE, an α4β2 nAChR antag-
onist, attenuates prefrontal serotonin release induced by s.c. 
administration of ketamine (Nishitani et  al., 2014), we inves-
tigated whether α4β2 nAChR in the DRN mediates prefrontal 
serotonin release induced by local perfusion of PPTg with keta-
mine. A  microinjection of DHβE (10  nmol) into the DRN sig-
nificantly attenuated serotonin release induced by intra-PPTg 
ketamine perfusion (F1,96 = 6.240, P < .05; Figure  2D). Previous 
studies have demonstrated that α4β2 nAChRs are present on 
serotonergic neurons and synaptic terminals of glutamatergic 
Figure 1. Pedunculopontine tegmental nucleus (PPTg) lesion attenuates ketamine-induced prefrontal 5-HT release. (A, C) Representative photomicrographs of choline 
acetyltransferase (ChAT) labeled cells in the PPTg (A) and the laterodorsal tegmental nucleus (LDTg) (C). (B, D) The number of ChAT-positive cells was significantly 
decreased in the PPTg (B) and LDTg (D). ***P < .001 vs sham-operated group (unpaired t test, n = 4–5). Scale bar = 200 µm (E, F). Effects of bilateral lesion of the PPTg (E) and 
LDTg (F) on ketamine-induced serotonin release in the mPFC. Extracellular serotonin levels in the mPFC were continuously measured for 120 min by in vivo microdialy-
sis before and after drug administration. Saline or ketamine (30 mg/kg) was administered s.c. at 0 min (arrow). ##P < .01 main effect in 2-way ANOVA, **P < .01, *P < .05 vs 
sham-operated group by Bonferroni posthoc test. n.s. not significant, n = 4–5. Basal values for serotonin concentrations were 0.51 ± 0.12 nM (PPTg-sham), 0.45 ± 0.04 nM 
(PPTg-lesion), 0.42 ± 0.06 nM (LDTg-sham), and 0.67 ± 0.16 nM (LDTg-lesion).
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neurons (Galindo-Charles et  al., 2008; Garduño et  al., 2012). 
To investigate whether the effect of intra-PPTg ketamine was 
mediated by enhancement of glutamate release through stimu-
lation of presynaptic α4β2 nAChR in the DRN, we examined the 
effect of intra-DRN injection of NBQX, an AMPA receptor antag-
onist. Similar to DHβE, intra-DRN injection of NBQX significantly 
attenuated prefrontal serotonin release induced by intra-PPTg 
ketamine perfusion (F1,96 = 6.201, P < .05; Figure 2D).
Discussion
In the present study, we showed that bilateral electrolytic lesion 
of the PPTg attenuated ketamine-induced prefrontal serotonin 
release and that unilateral perfusion of ketamine in the PPTg 
increased serotonin levels in the mPFC. Furthermore, pharma-
cological blockade of α4β2 nAChRs or AMPARs in the DRN sup-
pressed prefrontal serotonin release induced by local perfusion 
of ketamine in the PPTg. These results suggest that ketamine 
directly acts on the PPTg and induces serotonin release in the 
mPFC through activation of the DRN-projecting cholinergic neu-
rons in the PPTg and subsequently presynaptic α4β2 nAChRs in 
the DRN (supplementary Figure 1).
Consistent with the present findings, activation of presyn-
aptic α4β2 nAChRs results in the increase of serotonin neuronal 
firing through enhancement of glutamate release in the DRN 
(Garduño et al., 2012). Anatomical analyses have demonstrated 
that the DRN is innervated by cholinergic neurons from PPTg 
and LDTg (Woolf and Butcher, 1989). Surprisingly, in this study, 
PPTg but not LDTg was involved in ketamine-induced prefron-
tal serotonin release. One possible explanation for this differ-
ence between PPTg and LDTg is that ketamine preferentially 
activates PPTg cholinergic neurons. Indeed, local perfusion of 
ketamine in the PPTg but not in the LDTg mimicked the effect of 
ketamine, indicating different sensitivity to ketamine between 
these nuclei. On the other hand, PPTg and LDTg form rostrocau-
dal continuum of cholinergic neurons and have similar charac-
teristics of structure and neurochemistry (Paxinos and Watson, 
2007; Wang and Morales, 2009), suggesting similar sensitivity to 
pharmacological intervention.
Both PPTg and LDTg innervate basal ganglia and thalamic 
structures, such as substantia nigra pars compacta, ventral teg-
mental area, striatum, and thalamus as well as DRN. However, 
these projections do not overlap; PPTg neurons innervate lat-
eral region, whereas LDTg neurons innervate the medial region 
in these brain areas (Mena-Segovia, 2016). On the other hand, 
O’Hearn and Molliver have demonstrated that ventral rather 
than dorsal neurons in the DRN project to the cortex (O’Hearn 
and Molliver, 1984). Therefore, it is possible that PPTg and LDTg 
innervate different sub-nuclei in the DRN and that the PPTg 
preferentially connects to DRN serotonergic neurons projecting 
to mPFC, although further anatomical analyses are required.
In this study, prefrontal serotonin release was increased 
by local perfusion of PPTg with ketamine, strongly indicat-
ing that ketamine acts on the PPTg. However, it is unclear how 
ketamine, an NMDAR antagonist, activates cholinergic neuron 
in the PPTg. Several reports suggest that blockade of NMDARs 
Figure 2. α4β2 Nicotinic acetylcholine receptor (α4β2 nAChR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) in the dorsal raphe nu-
cleus (DRN) mediates prefrontal serotonin release induced by local perfusion of PPTg with ketamine. (A, B) Effects of local perfusion with ketamine of pedunculopon-
tine tegmental nucleus (PPTg) (A) and laterodorsal tegmental nucleus (LDTg) (B) on serotonin release in the medial prefrontal cortex (mPFC). Extracellular serotonin 
levels in the mPFC were continuously measured for 120 min by in vivo microdialysis before and after local perfusion with ketamine. The horizontal lines indicate 
the unilateral perfusion with vehicle or ketamine (0.1 mM). ##P < .01 main effect in 2-way ANOVA, ***P < .001, *P < .05 vs vehicle group by Bonferroni posthoc test. n.s., 
not significant, n = 3–6. Basal values for serotonin concentrations were 0.64 ± 0.17 nM (PPTg-vehicle), 0.50 ± 0.05 nM (PPTg-ketamine), 0.55 ± 0.05 nM (LDTg-vehicle), and 
0.49 ± 0.05 nM (LDTg-ketamine). (C) Schematic presentation of the experimental procedure. (D) Extracellular serotonin levels in the mPFC were continuously measured 
for 120 min before and after local perfusion of PPTg with ketamine by in vivo microdialysis. Saline, DHβE (10 nmol), an α4β2 nAChR antagonist, or NBQX (0.3 nmol), 
an AMPAR antagonist, was microinjected into the DRN from −15 to −10 min (bar). Then, ketamine (0.1 mM) was unilaterally perfused in the PPTg at 0 min (horizontal 
lines). #P < .05 main effect in 2-way ANOVA, ***P < .001, **P < .01, *P < .05 vs DRN-DHβE group by Bonferroni posthoc test. ††P < .01, †P < .05 vs DRN-NBQX group by Bonferroni 
posthoc test, n = 4–6. Basal values for serotonin concentrations were 0.45 ± 0.09 nM (DRN-saline), 0.44 ± 0.06 nM (DRN-DHβE), and 0.48 ± 0.09 nM (DRN-NBQX).
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increases activity of excitatory neurons by inhibiting GABAergic 
interneurons, and extracellular glutamate release in the mPFC 
(Moghaddam et  al., 1997; Homayoun and Moghaddam, 2007). 
Lines of evidence have demonstrated that PPTg contains 
GABAergic neurons as well as cholinergic neurons (Ford et al., 
1995; Wang and Morales, 2009). Thus, it is possible that ketamine 
activates cholinergic neurons through inhibiting NMDARs on 
GABA interneurons in the PPTg.
It is reported that social defeat stress suppresses the seroton-
ergic neuronal firing through increasing the activity of GABAergic 
interneurons in the DRN (Challis et  al., 2013), which partly 
explains why acute SSRI treatment is not effective in depressed 
animals (Berton et al., 2006). Meanwhile, we have reported that 
chronic SSRI treatment enhances serotonergic neuronal activity 
(Asaoka et al., 2017). The present study indicates that ketamine 
rapidly enhances serotonergic neuronal activity through α4β2 
nAChR stimulation, suggesting that ketamine is effective even 
in the mouse model in which acute SSRI is not effective. Indeed, 
efficacy of a single dose of ketamine is almost equivalent to that 
of chronic SSRI in social defeat paradigm wherein acute SSRI is 
ineffective (Donahue et al., 2014). Considering that antidepres-
sant-like effect of ketamine is attenuated by depletion of sero-
tonin or by inhibiting ketamine-induced prefrontal serotonin 
release (Gigliucci et al., 2013; Fukumoto et al., 2014), it is possible 
that increasing the serotonergic neuronal firing is important for 
achieving an antidepressive effect.
Furthermore, we found that the release of serotonin in the 
mPFC, induced by perfusion of the PPTg with ketamine, is sig-
nificantly attenuated by injection of NBQX to the DRN. These 
results indicate that enhancement of excitatory projection to 
DRN underlies the effect of ketamine. A previous report dem-
onstrated that optogenetic stimulation of the excitatory affer-
ents from mPFC to DRN leads to the activation of serotonergic 
neurons of the DRN (Challis et al., 2014). On the other hand, the 
same stimulation also leads to the activation of GABAergic neu-
rons of the DRN, which, in turn, inhibit serotonergic neurons 
(Challis et al., 2014). These observations indicate that these exci-
tatory projections exert a bidirectional effect on serotonergic ac-
tivity. Therefore, it is possible that the cholinergic afferents from 
PPTg to DRN preferentially enhance the excitatory afferents 
from mPFC leading to the activation of serotonergic neurons, 
although further histological and electrophysiological analyses 
would be required.
Our findings suggest that the DRN-projecting cholinergic 
neurons in the PPTg and α4β2 nAChR in the DRN play a key 
role in the effect of ketamine, but the role of cholinergic neu-
rons and α4β2 nAChR in the depressive behavior is controver-
sial. For example, acute stimulation of the α4β2 nAChR produces 
antidepressant-like responses in the learned helplessness 
model and the forced swim test (Ferguson et al., 2000), while the 
α4β2 nAChR antagonists also elicit antidepressant-like effects 
in forced swim test and tail suspension test (Andreasen et al., 
2009). α4β2 nAChRs are widely expressed in many brain regions 
associated with emotional behaviors, including basal ganglia, 
striatum, amygdala, ventral tegmental area, locus coeruleus, 
and DRN (Philip et  al., 2010). Because drugs are systemically 
administered in these previous reports, it is unclear which cho-
linergic neuronal circuit is important for antidepressant-like 
effects induced by respective drugs. Although further behavioral 
analyses are needed, PPTg-DRN cholinergic neurons may play a 
key role in the antidepressive effect of ketamine.
In conclusion, the present study revealed that ketamine 
increases serotonin release in the mPFC through directly acting 
on PPTg, and that α4β2 nAChR in the DRN mediates this effect. 
The present findings highlight the importance of the DRN-
projecting cholinergic neurons in PPTg in the effect of ketamine, 
which may contribute to rapid antidepressive effect of ketamine.
Supplementary Material
Supplementary data are available at International Journal of 
Neuropsychopharmacology online.
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